Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company's platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre- and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone. It also offers a medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, perioperative dressings, silicone dressings, vascular access line guards, and wound dressings; and surgical, peri-operative, and infection management products. It sells its products directly and through independent distributors under the ColActive, ColActive PLUS, CovaWound, CovaView, CovaClear IV, IV Clear, SurgiClear, MediClear, and VALGuard brands. The company serves health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care facilities, acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.…
Covalon Showcases Contamination Protection Solution at ANCC Magnet & Pathway 2026 Conference
Covalon Technologies (CVE: COV) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector.
The shares were at 3.700 CAD on 20 November 2026, up 80.5% over 52 weeks. Its 52-week range is 1.550 CAD to 4.590 CAD: the price is 19.4% below the high and 138.7% above the low.
At a market capitalisation of 102.19M CAD, it trades at 23.1 times trailing earnings and 18.5 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 48.3, a discount of 52% for COV.
Covalon Technologies reports return on equity of 6.7%, an operating margin of 11.5% and revenue up 19.9% year over year.
It holds more cash than debt, a net cash position of 17.70M CAD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 4.700 CAD is 27.0% above the current price. The next earnings report is expected on 17 December 2026.